EML4 and lung adenocarcinoma: For example, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) inhibitors are effective and used as first-line treatment agents for patients with adenocarcinoma of the lung who harbour EGFR-TKI-sensitive mutations or EML4-ALK rearrangement4, 5.